Could a cancer immunotherapy drug delay or stop smoldering myeloma?
NCT ID NCT02603887
First seen Jan 31, 2026 · Last updated May 25, 2026 · Updated 8 times
Summary
This early-phase trial tested the immunotherapy drug pembrolizumab in 20 adults with smoldering multiple myeloma at intermediate or high risk of progressing to active disease. The goal was to see if the drug could shrink or control the cancer and delay progression. Participants received pembrolizumab for up to 8 cycles, and researchers measured response rates and how many patients later developed active multiple myeloma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.